Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia
Abstract
We studied the effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum levels of lipoproteins and ubiquinone-10-in seven heterozygous patients with familial hypercholesterolemia. ML-236B was given at doses of 30 to 60 mg per day for 24 weeks. Serum cholesterol decreased from 390 +/- 9 to 303 +/- 8 mg per deciliter (101 +/- 0.2 to 7.88 +/- 0.2 mmol per liter, mean +/- S.E.M.; p less than 0.001) and serum triglyceride decreased from 137 +/- 18 to 87 +/- 9 mg per deciliter (1.55 +/- 0.20 to 0.98 +/- 0.01 mmol per liter; p less than 0.05). Intermediate-density-lipoprotein (DL) cholesterol, IDL triglyceride, low-density-lipoprotein (LDL) cholesterol, and LDL triglyceride decreased significantly (p less than 0.01, P less than 0.001, and P less than 0.001, respectively). However, there were no significant changes in very-low-density-lipoprotein (VLDL) cholesterol and triglyceride or high-density-lipoprotein (HDL) cholesterol. Serum ubiquinone-10 levels did not change, and LDL levels of ubiquinone-10 decreased by 50 per cent, from 0.39 +/- 0.07 to 0.20 +/- 0.01 microgram per milliliter (P less than 0.05). No adverse effects were observed. We conclude that ML-236B is effective in lowering serum cholesterol without lowering serum ubiquinone-10 in heterozygous patients with familial hypercholesterolemia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The co-administration of a nicotinic acid derivative (niacin) and statin to increase HDL-C levels did not have a suppressive effect on cardiovascular events in the AIM-HIGH and HPS2-THRIVE studies.
“Meanwhile, the co-administration of a nicotinic acid derivative (niacin) and statin to increase HDL-C levels did not have a suppressive effect on cardiovascular events in the AIM-HIGH653) and HPS2-THRIVE654) studies.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [654]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Enzymatic determination of total serum cholesterol.
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,845 · see citing works
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,756 · see citing works
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621 · see citing works
The Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis
Goldstein, L. J., & Brown, S. M. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004341 · Cited by 2,455 · see citing works
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750 · see citing works
Alberts, A. W., Chen, J., Kuron, G. W., Hunt, V. M., Huff, J. W., Hoffman, C., Rothrock, J. W., López, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,630 · see citing works
Brown, M. S., & Goldstein, J. L. (1980) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42221-7 · Cited by 1,210 · see citing works
A colorimetric method for estimating serum triglycerides
Fletcher, M. J. (1968) · Clinica Chimica Acta · doi:10.1016/0009-8981(68)90041-7 · Cited by 1,138 · see citing works
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
Endo, A., KURODA, M., & Tsujita, Y. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1346 · Cited by 954 · see citing works
Brown, M. S., Faust, J. R., Goldstein, J. L., Kaneko, I., & Endo, A. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38120-6 · Cited by 556 · see citing works
The Familial Hyperlipoproteinemias
Marion, M. S. (1975) · Cited by 526 · see citing works
Plasma High-Density Lipoproteins
Tall, A. R., & SMALL, D. M. (1978) · New England Journal of Medicine · doi:10.1056/nejm197811302992207 · Cited by 500 · see citing works
Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.
Kovanen, P. T., Bilheimer, D. W., Goldstein, J. L., Jaramillo, J. J., & Brown, M. S. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.2.1194 · Cited by 421 · see citing works
Enzyme Topology of Intracellular Membranes
DePierre, J. W., & Ernster, L. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.001221 · Cited by 386 · see citing works
Cholestyramine Promotes Receptor-Mediated Low-Density-Lipoprotein Catabolism
Shepherd, J., Packard, C. J., Bicker, S., Lawrie, T. D. V., & Morgan, H. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005293022202 · Cited by 356 · see citing works
Clofibrate and niacin in coronary heart disease
(1975) · JAMA · doi:10.1001/jama.231.4.360 · Cited by 297 · see citing works
Endo, A., Tsujita, Y., KURODA, M., & Tanzawa, K. (1977) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1977.tb11637.x · Cited by 263 · see citing works
Eisenberg, S., & Levy, R. I. (1975) · Advances in lipid research · doi:10.1016/b978-0-12-024913-8.50008-4 · Cited by 255 · see citing works
KANEKO, O., Yoko, H.-S., & Endo, A. (1978) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1978.tb12380.x · Cited by 249 · see citing works
THE LDL RECEPTOR LOCUS AND THE GENETICS OF FAMILIAL HYPERCHOLESTEROLEMIA
Goldstein, J. L., & Brown, M. S. (1979) · Annual Review of Genetics · doi:10.1146/annurev.ge.13.120179.001355 · Cited by 233 · see citing works
Therapeutic effects of ML-236B in primary hypercholesterolemia
Yamamoto, A., Sudo, H., & Endo, A. (1980) · Atherosclerosis · doi:10.1016/0021-9150(80)90124-0 · Cited by 231 · see citing works
Inhibition of cell growth by oxygenated derivatives of cholesterol
Chen, H. W., Kandutsch, A. A., & Waymouth, C. (1974) · Nature · doi:10.1038/251419a0 · Cited by 219 · see citing works
Cholestyramine Resin Therapy for Hypercholesteremia
Hashim, S. A. (1965) · JAMA · doi:10.1001/jama.1965.03080170017004 · Cited by 171 · see citing works
Synthesis of ubiquinone and cholesterol in human fibroblasts: Regulation of a branched pathway
Faust, J. R., Goldstein, J. L., & Brown, M. S. (1979) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(79)90074-2 · Cited by 151 · see citing works
REDUCTION OF SERUM-LIPID AND URIC-ACID LEVELS BY AN ORALLY ACTIVE ANDROSTERONE
Oliver, M. F. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92422-4 · Cited by 129 · see citing works
Goldstein, J. L., & Brown, M. S. (1975) · The American Journal of Medicine · doi:10.1016/0002-9343(75)90563-x · Cited by 114 · see citing works
Mabuchi, H., Ito, S., Haba, T., Ueda, K., Ueda, R., TATAMI, R., KAMETANI, T., Koizumi, J., Ohta, M., Miyamoto, S., et al. (1977) · Atherosclerosis · doi:10.1016/0021-9150(77)90199-x · Cited by 112 · see citing works
Self-citationTsujita, Y., Kuroda, M., Tanzawa, K., KITANO, N., & Endo, A. (1979) · Atherosclerosis · doi:10.1016/0021-9150(79)90174-6 · Cited by 112 · see citing works
Cholestyramine in Type II Hyperlipoproteinemia
Levy, R. I., FREDRICKSON, D. S., STONE, N. J., BILHEIMER, D. W., BROWN, W. V., GLUECK, C. J., Gotto, A. M., HERBERT, P. N., KWITEROVICH, P. O., LANGER, T., et al. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-1-51 · Cited by 99 · see citing works
Receptor-mediated catabolism of homologous low density lipoproteins in cultured pig hepatocytes.
Pangburn, S., Newton, R. S., Chang, C. M., Weinstein, D. B., & Steinberg, D. H. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69612-2 · Cited by 95 · see citing works
Kuroda, M., Tsujita, Y., Tanzawa, K., & Endo, A. (1979) · Lipids · doi:10.1007/bf02533537 · Cited by 81 · see citing works
Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia
Glueck, C. J. (1972) · JAMA · doi:10.1001/jama.222.6.676 · Cited by 75 · see citing works
Studies of Nicotinic Acid Use in Hypercholesteremia
PARSONS, W. B. (1961) · Archives of Internal Medicine · doi:10.1001/archinte.1961.03620050019003 · Cited by 71 · see citing works
Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemia
Miettinen, T. A. (1972) · Atherosclerosis · doi:10.1016/0021-9150(72)90066-4 · Cited by 70 · see citing works
Nambudiri, A. M. D., Ranganathan, S., & Rudney, H. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70714-5 · Cited by 60 · see citing works
Goh, E. H., & Heimberg, M. (1979) · Biochemical Journal · doi:10.1042/bj1840001 · Cited by 51 · see citing works
Determination of ubiquinone in serum and liver by high-speed liquid chromatography.
Abe, K., ISHIBASHI, K., OHMAE, M., KAWABE, K., & Katsui, G. (1978) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.24.555 · Cited by 36 · see citing works
Haba, T., Mabuchi, H., Yoshimura, A., Watanabe, A., WAKASUGI, T., Tatami, R., Ueda, K., Ueda, R., KAMETANI, T., Koizumi, J., et al. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110184 · Cited by 30 · see citing works
Self-citationMiller, N. E., & Nestel, P. J. (1975) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1975.tb00451.x · Cited by 16 · see citing works
Fixler, D. E., Watson, J. T., Wheeler, J. M., & Willerson, J. T. (1976) · Circulation · doi:10.1161/01.cir.54.1.26 · Cited by 13 · see citing works
Endo, A. (1980) · Springer eBooks · doi:10.1007/978-1-4612-6071-4_32 · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- [7]7. Tsujita Y, Kuroda M, Tanzawa K, Kitano N, Endo A. Hypolipidemic ei-- l -methylglutaryl coenzyme A reductase. Atherosclerosis. 1979; 32:307-13.
- [19]19. Miettinen TA. Changes in cholesterol metabolism by colestipol hydrochloride in hypercholesterolemic patients. Eur J Clin Invest. 1974; 4:365-6. abstract.
- [33]33. Eisenberg S, Levy RI. Lipoprotein metabolism. Adv Lipid Res. 1975; 13:1-89.
Cited by
Sorted by citations
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233 · see citing works
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 878 · see citing works
The discovery and development of HMG-CoA reductase inhibitors.
Endo, A. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41379-3 · Cited by 847 · see citing works
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 846 · see citing works
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813 · see citing works
HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 760 · see citing works
Bilheimer, D. W., Grundy, S. M., Brown, M. S., & Goldstein, J. L. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.13.4124 · Cited by 557 · see citing works
A historical perspective on the discovery of statins
Endo, A. (2010) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.86.484 · Cited by 550 · see citing works
Defective Lipoprotein Receptors and Atherosclerosis
Epstein, F. H., Goldstein, J. L., Kita, T., & Brown, M. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308043090507 · Cited by 468 · see citing works
Constituents of Red Yeast Rice, a Traditional Chinese Food and Medicine
Ma, J., Li, Y., Ye, Q., Li, J., Hua, Y., Ju, D., Zhang, D., Cooper, R., & Chang, M. N. T. (2000) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf000338c · Cited by 447 · see citing works
Ma, P. T. S., Gil, G., Südhof, T. C., Bilheimer, D. W., Goldstein, J. L., & Brown, M. S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.21.8370 · Cited by 334 · see citing works
Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03948.x · Cited by 324 · see citing works
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322 · see citing works
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 317 · see citing works
Pharmacology of competitive inhibitors of HMg-CoA reductase
Corsini, A. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80042-5 · Cited by 275 · see citing works
Reihnér, E., Rudling, M., Ståhlberg, D., Berglund, L., Ewerth, S., Björkhem, I., Einarsson, K., & Angelin, B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230403 · Cited by 277 · see citing works
Biologically active components and nutraceuticals in the Monascus-fermented rice: a review
Lin, Y.-L., Wang, T.-H., Lee, M.-H., & Su, N. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1256-6 · Cited by 262 · see citing works
1 The Discovery and Development of Atorvastatin, A Potent Novel Hypolipidemic Agent
Roth, B. D. (2002) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70080-8 · Cited by 235 · see citing works
From target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 222 · see citing works
Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial Hypercholesterolemia
Havel, R. J., HUNNINGHAKE, D. B., ILLINGWORTH, D. R., Lees, R. S., STEIN, E. A., TOBERT, J. A., BACON, S. R., BOLOGNESE, J. A., FROST, P. H., LAMKIN, G. E., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-609 · Cited by 212 · see citing works
Pathogenesis and Management of Lipoprotein Disorders
Flier, J. S., Underhill, L. H., Schaefer, E. J., & Levy, R. I. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505163122007 · Cited by 213 · see citing works
Grundy, S. M., & Vega, G. L. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34252-8 · Cited by 208 · see citing works
Steinberg, D. H. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600009-jlr200 · Cited by 201 · see citing works
Tobert, J. A., Bell, G. D., Birtwell, J., James, I. M., Kukovetz, W. R., Pryor, J., Buntinx, A., Holmes, I. B., Chao, Y. S., & Bolognese, J. A. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110530 · Cited by 204 · see citing works
Reduction of Serum Cholesterol in Heterozygous Patients with Familial Hypercholesterolemia
Mabuchi, H., Sakai, T., Sakai, Y., Yoshimura, A., Watanabe, A., WAKASUGI, T., Koizumi, J., & Takeda, R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303173081101 · Cited by 198 · see citing works
Self-citationKim, R. G., Loomba, R. S., Prokop, L. J., & Singh, S. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.039 · Cited by 193 · see citing works
A new grammar for drug discovery
Fishman, M. C., & Porter, J. A. (2005) · Nature · doi:10.1038/437491a · Cited by 193 · see citing works
Pathogenesis and Management of Lipoprotein Disorders
Fredman, S. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603273141310 · Cited by 187 · see citing works
Illingworth, D. R., & Sexton, G. J. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111618 · Cited by 170 · see citing works
Olson, R. E., & Rudney, H. (1983) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60431-8 · Cited by 165 · see citing works
Parker, F. S. (1985) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(85)70139-9 · Cited by 166 · see citing works
Lovastatin for Lowering Cholesterol Levels in Non-Insulin-Dependent Diabetes Mellitus
Garg, A., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180204 · Cited by 158 · see citing works
EFFECTS OF SYNVINOLIN (MK-733) ON PLASMA LIPIDS IN FAMILIAL HYPERCHOLESTEROLAEMIA
Mol, M. J. T. M., Leuven, J. A. G., Erkelens, D. W., Schouten, T. A., & Stalenhoef, A. F. H. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90598-2 · Cited by 156 · see citing works
A gift from nature: the birth of the statins
Endo, A. (2008) · Nature Medicine · doi:10.1038/nm1008-1050 · Cited by 152 · see citing works
Lowering Plasma Cholesterol by Raising LDL Receptors
Brown, M. S., & Goldstein, J. L. (1981) · New England Journal of Medicine · doi:10.1056/nejm198108273050909 · Cited by 142 · see citing works
Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia
Illingworth, D. R. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-5-598 · Cited by 129 · see citing works
Maltese, W. A., Defendini, R., Green, R. A., Sheridan, K. M., & Donley, D. K. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112165 · Cited by 124 · see citing works
Grundy, S. M., & Bilheimer, D. W. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.8.2538 · Cited by 123 · see citing works
The synthesis of mevinic acids
Rosen, T., & Heathcock, C. H. (1986) · Tetrahedron · doi:10.1016/s0040-4020(01)88045-5 · Cited by 120 · see citing works
Mabuchi, H., Higashikata, T., Kawashiri, M., Katsuda, S., Mizuno, M., Nohara, A., Inazu, A., Koizumi, J., & Kobayashi, J. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.111 · Cited by 119 · see citing works
Self-citationHoeg, J. M., & Brewer, H. B. (1987) · PubMed · Cited by 118 · see citing works
Combination Drug Therapy for Familial Combined Hyperlipidemia
East, C. A., Bilheimer, D. W., & Grundy, S. M. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-1-25 · Cited by 118 · see citing works
Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors
Jamal, S. M., Eisenberg, M. J., & Christopoulos, S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.12.037 · Cited by 111 · see citing works
Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.
Watts, G. F., Castelluccio, C., Rice-Evans, C. A., Taub, N. A., Baum, H., & Quinn, P. J. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.11.1055 · Cited by 109 · see citing works
Statin use is associated with lower disease severity in COVID-19 infection
Tan, W. Y. T., Young, B. E., Lye, D. C., Chew, D. E. K., & Dalan, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74492-0 · Cited by 106 · see citing works
Grundy, S. M., Vega, G. L., & Bilheimer, D. W. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-3-339 · Cited by 106 · see citing works
Nakamura, C. E., & Abeles, R. H. (1985) · Biochemistry · doi:10.1021/bi00327a014 · Cited by 105 · see citing works
Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus ruber.
Endo, A., Hasumi, K., & Negishi, S. (1985) · The Journal of Antibiotics · doi:10.7164/antibiotics.38.420 · Cited by 103 · see citing works
Mosley, S. T., Kalinowski, S. S., Schafer, B. L., & Tanaka, R. D. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38255-9 · Cited by 103 · see citing works
Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan
Mabuchi, H. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16008 · Cited by 102 · see citing works
Self-citationPasha, M. K., Syed, M., Shaik, J. S., Shashikumar, D., Mullangi, R., & Srinivas, N. R. (2005) · Biomedical Chromatography · doi:10.1002/bmc.561 · Cited by 101 · see citing works
Singer, I. I., Kawka, D. W., Kazazis, D. M., Alberts, A. W., Chen, J. S., Huff, J. W., & Ness, G. C. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.17.5556 · Cited by 99 · see citing works
Influence of probucol on cholesterol and lipoprotein metabolism in man.
Kesäniemi, Y. A., & Grundy, S. M. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37741-5 · Cited by 96 · see citing works
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94 · see citing works
Laaksonen, R., Ojala, J.-P., Tikkanen, M. J., & Himberg, J. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00194398 · Cited by 94 · see citing works
Mevastatin inhibits ovarian theca–interstitial cell proliferation and steroidogenesis
Izquierdo, D. M., Foyouzi, N., Kwintkiewicz, J., & Dulęba, A. J. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.03.037 · Cited by 90 · see citing works
Update on statin-mediated anti-inflammatory activities in atherosclerosis
Montecucco, F., & Mach, F. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0150-y · Cited by 89 · see citing works
Malloy, M. J., KANE, J. P., KUNITAKE, S. T., & TUN, P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-616 · Cited by 87 · see citing works
Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma
Berthold, H. K., Naini, A., Mauro, S. D., Hallikainen, M., Gylling, H. K., Krone, W., & Gouni‐Berthold, I. (2006) · Drug Safety · doi:10.2165/00002018-200629080-00007 · Cited by 86 · see citing works
Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia
Hoeg, J. M., Maher, M. B., Zech, L. A., Bailey, K. R., Gregg, R. E., Lackner, K. J., Fojo, S. S., Anchors, M., Bojanovski, M., Sprecher, D. L., et al. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90733-2 · Cited by 82 · see citing works
Clarke, C. F., Williams, W., & Teruya, J. H. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55349-7 · Cited by 81 · see citing works
The Effect of CS-514 on Serum Lipids and Apolipoproteins in Hypercholesterolemic Subjects
Nakaya, N. (1987) · JAMA · doi:10.1001/jama.1987.03390220086026 · Cited by 81 · see citing works
Mol, M. J. T. M., Erkelens, D. W., Leuven, J. A. G., Schouten, J. A., & Stalenhoef, A. F. H. (1988) · Atherosclerosis · doi:10.1016/0021-9150(88)90006-8 · Cited by 79 · see citing works
Peripheral neuropathy associated with simvastatin.
Phan, T. G., McLeod, J. G., Pollard, J. D., Peiris, O. A., Rohan, A., & Halpern, J. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.58.5.625 · Cited by 77 · see citing works
Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76 · see citing works
Suppression of principal atherosclerotic mechanisms by prostacyclinc and other eicosanoids
Willis, A. L., Smith, D. L., & Vigo, C. (1986) · Progress in Lipid Research · doi:10.1016/0163-7827(86)90132-3 · Cited by 76 · see citing works
Statins—From Fungi to Pharmacy
Sadowska, A. J., Osiński, P., Roztocka, A., Kaczmarz-Chojnacka, K., Zapora, E., Sawicka, D., & Car, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010466 · Cited by 77 · see citing works
Elmberger, P. G., Kalén, A., Lund, E. G., Reihnér, E., Eriksson, M., Berglund, L., Angelin, B., & Dallner, G. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41990-x · Cited by 72 · see citing works
An Approach to the Management of Hyperlipoproteinemia
Hoeg, J. M. (1986) · JAMA · doi:10.1001/jama.1986.03370040086030 · Cited by 71 · see citing works
Impact of Statin Treatment on the Clinical Fate of Heterozygous Familial Hypercholesterolemia
Harada-Shiba, M., Sugisawa, T., Makino, H., Abe, M., Tsushima, M., Yoshimasa, Y., Yamashita, T., Miyamoto, Y., Yamamoto, A., Tomoike, H., et al. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.4143 · Cited by 70 · see citing works
Metabolic modes of action of the statins in the hyperlipoproteinemias
Aguilar-Salinas, C. A., Barrett, P. H. R., & Schonfeld, G. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00198-1 · Cited by 70 · see citing works
Toker, S. E., Önal, A., & Çetin, S. M. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(03)00314-3 · Cited by 69 · see citing works
Bargossi, A., Grossi, G., Fiorella, P. L., Gaddi, A. V., Giulio, R. D., & Battino, M. A. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90028-0 · Cited by 69 · see citing works
Bargossi, A., Battino, M. A., Gaddi, A. V., Fiorella, P. L., Grossi, G., Barozzi, G., Giulio, R. D., Descovich, G. C., Sassi, S., Genova, M. L., et al. (1994) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02592449 · Cited by 69 · see citing works
Endo, A., & Hasumi, K. (1993) · Natural Product Reports · doi:10.1039/np9931000541 · Cited by 68 · see citing works
Hajar, R. (2011) · Heart Views · doi:10.4103/1995-705x.95070 · Cited by 67 · see citing works
Lipid lowering agents of natural origin: An account of some promising chemotypes
Singh, S. P., & Sashidhara, K. V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.020 · Cited by 66 · see citing works
LOVASTATIN, ISOPRENES, AND MYOPATHY
Walravens, P., Greene, C. L., & Frerman, F. E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91108-2 · Cited by 66 · see citing works
Screening Asymptomatic Adults for Cardiac Risk Factors: The Serum Cholesterol Level
Garber, A. M., Sox, H. C., & Littenberg, B. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-8-622 · Cited by 63 · see citing works
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia
Illingworth, D. R., & Bacon, S. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90589-3 · Cited by 62 · see citing works
CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
van der Ende, E. L., Veld, S. G. J. G. I. ‘., Hanskamp, I., van der Lee, S. J., Dijkstra, J. I. R., Hok‐A‐Hin, Y. S., Blujdea, E. R., Swieten, J. C. V., Irwin, D. J., Chen‐Plotkin, A. S., et al. (2023) · Brain · doi:10.1093/brain/awad213 · Cited by 55 · see citing works
Shinohara, M., Sato, N., Shimamura, M., Kurinami, H., Hamasaki, T., Chatterjee, A., Rakugi, H., & Morishita, R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00071 · Cited by 59 · see citing works
Chao, Y., Kroon, P. A., Yamin, T.-T., Thompson, G. M., & Alberts, A. W. (1983) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(83)90154-6 · Cited by 55 · see citing works
Stone, B. G., Evans, C. D., Prigge, W. F., Duane, W. C., & Gebhard, R. L. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38206-7 · Cited by 53 · see citing works
Maltese, W. A., & Aprille, J. R. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39062-2 · Cited by 53 · see citing works
Mabuchi, H., KAMON, N., Fujita, H., Michishita, I., TAKEDA, M., Kajinami, K., Itoh, H., WAKASUGI, T., & Takeda, R. (1987) · Metabolism · doi:10.1016/0026-0495(87)90046-1 · Cited by 53 · see citing works
Self-citationLovastatin in the Treatment of Multifactorial Hyperlipidemia Associated With Proteinuria
Golper, T. A., Illingworth, D. R., Morris, C. D., & Bennett, W. M. (1989) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(89)80038-1 · Cited by 53 · see citing works
Uusitupa, M. I. J., Miettinen, T. A., Happonen, P., Ebeling, T., Turtola, H., Voutilainen, E., & Pyörälà, K. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.7.807 · Cited by 52 · see citing works
Inhibition of cholesterol synthesis by ketoconazole
Kraemer, F. B., & Pont, A. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90816-8 · Cited by 50 · see citing works
Robinson, J. R., Denny, J. C., Roden, D. M., & Driest, S. L. V. (2017) · Clinical and Translational Science · doi:10.1111/cts.12522 · Cited by 48 · see citing works
Intracellular tPA–PAI-1 interaction determines VLDL assembly in hepatocytes
Dai, W., Zhang, H., Lund, H., Zhang, Z., Castleberry, M., Rodriguez, M., Kuriakose, G., Gupta, S. K., Lewandowska, M., Powers, H. R., et al. (2023) · Science · doi:10.1126/science.adh5207 · Cited by 47 · see citing works
Simvastatin: A Review of its Pharmacology and Clinical Use
Mauro, V. F., & MacDonald, J. L. (1991) · DICP · doi:10.1177/106002809102500309 · Cited by 47 · see citing works
The Effect of CS-514, an Inhibitor of HMG-CoA Reductase, on Serum Lipids in Healthy Volunteers
Nakaya, N., Homma, Y., TAMACHI, H., & Goto, Y. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90071-7 · Cited by 47 · see citing works
Pappu, A. S., Illingworth, D. R., & Bacon, S. (1989) · Metabolism · doi:10.1016/0026-0495(89)90214-x · Cited by 44 · see citing works
Illingworth, D. R., & Tobert, J. A. (2001) · Advances in protein chemistry · doi:10.1016/s0065-3233(01)56003-9 · Cited by 43 · see citing works
Markowska, A., Antoszczak, M., Markowska, J., & Huczyński, A. (2020) · Pharmaceuticals · doi:10.3390/ph13120422 · Cited by 42 · see citing works
Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat
Lőw, P., Andersson, M., Edlund, C., & Dallner, G. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90081-6 · Cited by 42 · see citing works
Schulzeck, P., Jochim, A., Bojanovski, M., Canzler, H., & Bojanovski, D. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91414-6 · Cited by 42 · see citing works
Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression
Cleland, J. G. F., & McGowan, J. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199906003-00003 · Cited by 42 · see citing works
A tribute to Akira Endo, discoverer of a “Penicillin” for cholesterol
Brown, M. S., & Goldstein, J. L. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.007 · Cited by 41 · see citing works
- Authors
- Mabuchi, H., Haba, T., Tatami, R., Miyamoto, S., Sakai, Y., Wakasugi, T., Watanabe, A., Koizumi, J., & Takeda, R.
- Affiliations
- Kanazawa University (JP)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1981-08-27
- Volume
- 305
- Issue
- 9
- Pages
- 478-482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2051105453
- Cited by
- 262
- References
- 41
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 8 · 2022: 2 · 2021: 6 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 2 · 2012: 2
- FWCI
- 25.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- ML-236B, statins, familial hypercholesterolemia, serum cholesterol, serum triglycerides, lipoproteins, LDL cholesterol, intermediate density lipoprotein, ubiquinone-10
- MeSH terms
- Adult, Aged, Cholesterol, Female, Heterozygote, Humans, Hyperlipoproteinemia Type II, Lipoproteins, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Lovastatin, Male, Middle Aged, Naphthalenes, Triglycerides, Ubiquinone, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
